All patients (n = 554) | P value | Propensity score-matched patients (n = 432) | P value | |||
---|---|---|---|---|---|---|
EW group (n = 239) | LW group (n = 315) | EW group (n = 216) | LW group (n = 216) | |||
Operative time, minutes (median, IQR) | 350 (290–421) | 345 (277–420) | 0.530 | 350 (290–420) | 341 (280–420) | 0.703 |
Operative blood loss, grams (median, IQR) | 202 (39–482) | 265 (45–645) | 0.095 | 195 (30–460) | 230 (40–639) | 0.182 |
Blood transfusion (n, %) | 0.581 | 0.499 | ||||
Not performed | 198 (82.9%) | 255 (80.9%) | 181 (83.8%) | 187 (86.6%) | ||
Performed | 41 (17.1%) | 60 (19.1%) | 35 (16.2%) | 29 (13.5%) | ||
Hospital stay after surgery, days (median, IQR) | 13 (11–17) | 13 (11–18) | 0.47 | 13 (10–17) | 13 (10–18) | 0.907 |
Death within 30 days after surgery (n, %) | 0 | 2 (0.6%) | 0.508 | 0 | 2 (0.9%) | 0.499 |
In-hospital death (n, %) | 0 | 4 (1.3%) | 0.137 | 0 | 2 (0.9%) | 0.499 |
Adjuvant chemotherapy (n, %) | 0.211 | 0.788 | ||||
Absent | 204 (85.4%) | 255 (81.0%) | 182 (84.3%) | 185 (85.7%) | ||
Present | 35 (14.6%) | 60 (19.0%) | 34 (15.7%) | 31 (14.3%) | ||
Tumor diameter, mm (median, IQR) | 35 (25–50) | 35 (22–60) | 0.318 | 35 (25–50) | 34 (20–50) | 0.531 |
Retrieved number of lymph nodes (median, IQR) | 40 (27–50) | 38 (26–53) | 0.922 | 39 (27–49) | 38 (25–53) | 0.930 |
Pathological tumor depth (n, %) | 0.049 | 0.660 | ||||
pT1 | 134 (56.1%) | 150 (47.6%) | 123 (56.9%) | 119 (55.1%) | ||
pT2 | 41 (17.1%) | 53 (16.8%) | 39 (18.1%) | 40 (18.5%) | ||
pT3 | 43 (18.0%) | 61 (19.4%) | 39 (18.1%) | 35 (16.2%) | ||
pT4 | 21 (8.8%) | 51 (16.2%) | 15 (6.9%) | 22 (10.2%) | ||
Pathological lymph node metastasis (n, %) | 0.018 | 0.844 | ||||
pN0 | 173 (72.4%) | 204 (64.8%) | 156 (72.2%) | 161 (74.5%) | ||
pN1 | 29 (12.1%) | 49 (15.6%) | 29 (13.4%) | 24 (11.1%) | ||
pN2 | 10 (4.2%) | 33 (10.5%) | 10 (4.6%) | 12 (5.6%) | ||
pN3 | 27 (11.3%) | 29 (9.2%) | 21 (9.7%) | 19 (8.8%) | ||
Pathological TNM stage (n, %) | 0.075 | 0.992 | ||||
IA | 120 (50.2%) | 136 (43.2%) | 109 (50.5%) | 109 (50.5%) | ||
IB | 42 (17.6%) | 47 (14.9%) | 40 (18.5%) | 41 (19.0%) | ||
IIA | 24 (10.0%) | 35 (11.1%) | 23 (10.7%) | 24 (11.1%) | ||
IIB | 19 (8.0%) | 33 (10.5%) | 16 (7.4%) | 12 (5.6%) | ||
IIIA | 8 (3.4%) | 37 (11.8%) | 8 (3.7%) | 10 (4.6%) | ||
IIIB | 20 (8.4%) | 17 (5.4%) | 15 (6.9%) | 15 (6.9%) | ||
IIIC | 6 (2.5%) | 10 (3.2%) | 5 (2.3%) | 5 (2.3%) |